

# An End-to-End Cell & Gene Therapy Development Partnership



Cell and gene therapies are continuing to gain popularity, with 15 now FDA approved<sup>1</sup> and hundreds more in development. While these treatments are promising, managing safety and effectiveness in patients is complex. Around the world, groups ranging from drug discovery, development, and manufacturing to clinical laboratories are using Bio-Rad's *Droplet Digital PCR* technology as a reliable and scalable solution to myriad workflow challenges.

In Process Testing	<b>WHY CELL &amp; GENE THERAPY SCIENTISTS TRUST ddPCR...</b>				<b>Key Benefits</b> + Precision + Accuracy + Inhibitor Tolerance/Sensitivity + Multiplexing
	 Plasmid Integrity	 Viral Titer	 Transgene Copy Number	 Transgene Expression	Goals: CMC submissions, efficient and scalable process development
Final QA/QC	<b>WHY QA/QC SCIENTISTS TRUST ddPCR...</b>				
	 Residual DNA	 Viral Titer	 Mycoplasma Detection	 Transgene Copy Number	Goals: Reliable assessments of purity, potency and safety
Clinical Research	<b>WHY CLINICAL RESEARCHERS TRUST ddPCR...</b>				
	 Serial Monitoring	 Biodistribution	 Dose Response Evaluation	Goals: Effective evaluation of cell & gene therapies in patients	

Explore Bio-Rad's end-to-end solutions for developing and manufacturing cell and gene therapies at [www.bio-rad.com/cgtresources](http://www.bio-rad.com/cgtresources)

1. Center for Biologics Evaluation and Research. Approved cellular and gene therapy products. Retrieved July 01, 2021, from <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapyproducts/approved-cellular-and-gene-therapy-products>